Harnessing genomics to improve health in the Eastern Mediterranean Region – an executive course in genomics policy by Acharya, Tara et al.
BioMed  Central
Page 1 of 11
(page number not for citation purposes)
Health Research Policy and Systems
Open Access Commentary
Harnessing genomics to improve health in the Eastern 
Mediterranean Region – an executive course in genomics policy
Tara Acharya1, Mohammed Abdur Rab2, Peter A Singer1,3 and 
Abdallah S Daar*1,4,5,6
Address: 1Joint Center for Bioethics, University of Toronto, 88 College Street, Toronto, ON – M5G 1L4, Canada, 2World Health Organization, 
Eastern Mediterranean Regional Office, Cairo, Egypt, 3Faculty of Medicine, University of Toronto, 1 King's College Circle, Toronto, Ontario – M5S 
1A8, Canada, 4Department of Public Health Sciences, University of Toronto, 12 Queen's Park Crescent W. Toronto, ON – M5S 1A8 Canada, 
5Department of Surgery, University of Toronto, Banting Institute, 100 College Street, Toronto, ON – M5G 1L5 Canada and 6The McLaughlin 
Centre for Molecular Medicine, University of Toronto, 620 University Avenue, Toronto, ON – M5G 2C1 Canada
Email: Tara Acharya - tara_acharya@utoronto.ca; Mohammed Abdur Rab - abdurrabm@emro.who.int; 
Peter A Singer - peter.singer@utoronto.ca; Abdallah S Daar* - a.daar@utoronto.ca
* Corresponding author    
Abstract
Background: While innovations in medicine, science and technology have resulted in improved
health and quality of life for many people, the benefits of modern medicine continue to elude
millions of people in many parts of the world. To assess the potential of genomics to address health
needs in EMR, the World Health Organization's Eastern Mediterranean Regional Office and the
University of Toronto Joint Centre for Bioethics jointly organized a Genomics and Public Health
Policy Executive Course, held September 20th–23rd, 2003, in Muscat, Oman. The 4-day course was
sponsored by WHO-EMRO with additional support from the Canadian Program in Genomics and
Global Health. The overall objective of the course was to collectively explore how to best harness
genomics to improve health in the region. This article presents the course findings and
recommendations for genomics policy in EMR.
Methods: The course brought together senior representatives from academia, biotechnology
companies, regulatory bodies, media, voluntary, and legal organizations to engage in discussion.
Topics covered included scientific advances in genomics, followed by innovations in business
models, public sector perspectives, ethics, legal issues and national innovation systems.
Results: A set of recommendations, summarized below, was formulated for the Regional Office,
the Member States and for individuals.
• Advocacy for genomics and biotechnology for political leadership;
• Networking between member states to share information, expertise, training, and regional
cooperation in biotechnology; coordination of national surveys for assessment of health
biotechnology innovation systems, science capacity, government policies, legislation and
regulations, intellectual property policies, private sector activity;
• Creation in each member country of an effective National Body on genomics, biotechnology and
health to:
- formulate national biotechnology strategies
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- raise biotechnology awareness
- encourage teaching and training of biotechnology
- devise integration of biotechnology within national health systems.
Conclusion: The recommendations provide the basis for a road map for EMR to take steps to
harness biotechnology for better and more equitable health. As a result of these recommendations,
health ministers from the region, at the 50th Regional Committee Meeting held in October 2003,
have urged Member States to establish national bodies of biotechnology to formulate a strategic
vision for developing biotechnology in the service of the region's health. These efforts promise to
raise the profile of genomics in EMR and increase regional cooperation in this exciting new field.
Background
In a recent study, University of Toronto researchers iden-
tified the "Top 10 Biotechnologies to Improve Health in
Developing Countries" [1]. The study underscores the
importance of harnessing new technologies to improve
global health and development, a belief that is gaining
widespread acceptance. For instance, the overall goal of
the United Nations Millennium Project's Science and
Technology Task Force is to address how science and tech-
nology can be leveraged to help countries achieve the Mil-
lennium Development Goals (MDGs) [2]. Its mission is
guided by the understanding that most of the MDGs can-
not be reached without a strong contribution from science
and technology. The potential contribution of genomics
and biotechnology to these goals has also been demon-
strated [3]. However, these technologies are most benefi-
cial to countries that have the scientific capacity to absorb
and use them. The aim of the Inter-Academy Council on
Science and Technology Capacity (IAC) was to develop a
global strategy for promoting capacities in science and
technology and the first report of the Council was recently
presented to UN Secretary General Kofi Annan [4].
There is a wide range of scientific capacity and health sys-
tem development across the Eastern Mediterranean
Region (EMR) [5], which consists of 21 countries. Some
countries in the region have taken the initiative in bio-
technology by establishing regulations and encouraging
private sector involvement. In other countries of the
region, there is a serious lack of scientific capacity not only
to conduct research and development in biotechnology
but even to absorb the benefits of biotechnology and
apply them to help meet the health and socio-economic
needs of the population [6]. According to UNDP's Arab
Human Development Report 2003, research and develop-
ment in the Arab world represents less than 0.2% of Gross
National Product (GNP). Fewer than one in 20 Arab uni-
versity students were pursuing scientific disciplines, com-
pared, for instance, to one in five in South Korea [7]. There
is a risk that, as the genomics revolution gathers momen-
tum, the imminent genomics divide between developed
and developing countries will increase unless urgent
action is taken to reverse the trend [8].
In order to assess the potential of genomics to address
health needs in the Region, the World Health Organiza-
tion-Eastern Mediterranean Regional Office (WHO-
EMRO) and the University of Toronto Joint Centre for
Bioethics jointly organized a Genomics and Public Health
Policy Executive Course, held September 20th–23rd, 2003,
in Muscat, Oman. This 4-day course/workshop was spon-
sored by WHO-EMRO with additional support from the
Canadian Program in Genomics and Global Health.
The overall objective of the Genomics Policy Executive
Course was to familiarize participants with the potential
of genomics and related biotechnologies to address health
needs and to collectively address the question of how best
to harness genomics to improve health in the region
(table 1).
Methods
We based the program and designed the sessions and lec-
ture topics of this course on prior courses held in Nairobi,
Kenya in March 2002; in Toronto, Canada in May 2002;
and in Kumarakom, India in January 2003. The sessions
and presenters of the course are shown in table 2. The
Table 1: Objectives of the Genomics Policy Executive Course
To familiarize participants with the current status and implications of 
health genomics/biotechnology, and to provide information relevant 
to public policy on health genomics/biotechnology
To provide frameworks for analyzing and debating the policy issues 
and related ethical questions in health genomics/biotechnology, and to 
help understand, anticipate and possibly influence the legal and 
regulatory frameworks under which health biotechnology industries 
will operate, both nationally and internationally
To begin developing an opinion-leaders network across different 
sectors (industry, academic, government, NGOs) by sharing 
perspectives and building relationship
To formulate recommendations for future policy and strategic 
directions at the regional, national and individual levels.Health Research Policy and Systems 2005, 3:1 http://www.health-policy-systems.com/content/3/1/1
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course participants and facilitators for each session were
identified through a combination of recommendations
from field experts in the region and from WHO's network
of experts. People identified to participate in the course
included scientists from academic institutions and indus-
try, industry executives, regulatory officials, representa-
Table 2: Program
Saturday, 20 September 2003
08:00 – 08:30 Registration
08:30 – 10:30 Session I:
Opening Address
H.E. Dr Ali Bin Moosa, Minister of Health, Oman
Dr H. A. Gezairy, Regional Director, EMRO
Introduction and Course Overview
Team from University of Toronto
Session Chair: Dr Ali Jaffer Suleiman, Ministry of Health, Oman
10:30 – 11:00 Coffee break
11:00 – 12:30 Genomics: Scientific Developments
Professor Riad Bayoumi, Sultan Qaboos University
12:30 – 14:00 Lunch Break
14:00 – 15:30 Session III:
WHO Report on Genomics and World Health
Professor Alexander Capron, Director, Department of Ethics, Trade and 
Human Rights, WHO/HQ
15:30 – 16:00 Coffee break
15:45 – 16:30 Session IV:
Top 10 Biotechnologies for Improving Health in Developing Countries 
Professor Abdallah S. Daar, University of Toronto
Sunday, 21 September 2003
08:30 – 09:00 Golden Nuggets (previous day's summary)
Dr Peter A. Singer, University of Toronto
09:00 – 10:30 Islamic Perspective on Stem Cells, Cloning, Genetic Engineering, ..etc
Dr Mohammed Al Bar, King Fahd Medical Research Centre, Saudi Arabia
10:30 – 11:00 Coffee break
01:00 – 12:30 Intellectual Property Rights
Professor Richard Gold, McGill University, Centre for Intellectual 
Property Policy
12:30: – 14:00 Lunch Break
14:00 – 15:30 Business Models
Mr Khalil Ahmed, Managing Director, Shantha Biotech, India
Dr Peter A. Singer, University of Toronto
15:30 – 16:00 Coffee break
16:00 – 17:30 Group Work
Monday, 22 September 2003
08:30 – 09:00 Golden Nuggets (previous day's summary)
Dr Peter A. Singer, University of Toronto
09:00 – 10:30 Innovation Systems
Dr Peter A. Singer, University of Toronto
10:30 – 11:00 Coffee break
11:00 – 12:30 Regulatory Systems and Related Issues
Dr D.C. Jayasuriya, Director, UNAIDS, Pakistan
Dr Anwar Nasim, Chairman, National Council of Biotechnology, Pakistan
12:30 – 13:00 TRIPS and Pharmaceutical Issues in Public Health.
Dr. Abdel Aziz Saleh Special Advisor to the Regional Director for Medicine, 
WHO/EMRO
13:00 – 14:00 Lunch Break
14:30 – 15:30 Public Engagement
Mr Ehsan Masood, Scidev.net, United Kingdom
15:30 – 16:00 Coffee Break
16:00 – 17:30 Group WorkHealth Research Policy and Systems 2005, 3:1 http://www.health-policy-systems.com/content/3/1/1
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tives from the legal sector, and media. The participants
were carefully chosen in an attempt to represent a wide
range of interests relevant to the emerging area of genom-
ics and to have geographical, discipline and gender bal-
ance. They included scientists from academic institutions
and industry, industry executives, legal and regulatory
officials, WHO representatives and the media. In total
there were 51 participants, from 13 countries of EMR. We
drew as many of the faculty as possible from the region.
The sessions dealt with a wide range of relevant topics,
starting with recent scientific advances in genomics and
stem cell research, followed by discussions on business
models in genomics and biotechnology, intellectual prop-
erty rights and regulatory frameworks, public engagement
and an internet-based opinion leaders' network. The pres-
entations were designed to be interactive and foster active
discussion from, and among, the participants, and each
presentation was followed by a moderated discussion
period. Early in the course, the attendees were placed into
one of five study groups – these groups were carefully
designed to capitalize on the diverse backgrounds of the
participants. Each group was assigned the task to on the
deliberate the key question "How best to harness genom-
ics and biotechnology to improve the health of the peo-
ple in the Eastern Mediterranean Region?" The groups
met frequently to discuss the presentations, and each par-
ticipant was also provided a course reader with additional
literature on the lecture topics (table 3). The overall task
of these study groups was to draw upon the course mate-
rial and their own experiences and propose a set of recom-
mendations for genomics and biotechnology policy in the
region. On the last day of the meeting each group pre-
sented these recommendations.
In order to assess the level of interest in the formation of
an email-based opinion leaders' network to continue dis-
Tuesday, 23 September 2003
08:30 – 09:00 Golden Nuggets (previous day's summary)
Dr Peter A. Singer, University of Toronto
09:00 – 10:00 Opinion Leaders Network
Dr Peter A. Singer, University of Toronto, Dr Tara Acharya, University of 
Toronto
10:00 – 10:30 Break
10:30 – 12:30 Group Work
12:30 – 14:00 Lunch break
14:00 – 15:30 Group Presentations and Discussion
15:30 – 16:00 Coffee Break
16:00 – 17:30 Recommendations, Concluding Remarks and Closure of the Workshop
Dr Peter Singer, University of Toronto
Table 2: Program (Continued)
Table 3: Course Readings
Bhutta ZA (2002) Ethics in international health research: a 
perspective from the developing world.
Bull World Health Organ.;80(2):114–20. Review.
Bloom BR & Trach D (2001) Genetics and Developing Countries. 
BMJ;322:1006–7.
Capron AM (2001) Stem Cells: Ethics, Law and Politics. Biotech Law 
Report;5:678–699.
Collins FS, Green ED, Guttmacher AE, Guyer MS; US National 
Human Genome Research Institute. (2003) A vision for the future of 
genomics research.
Nature.24;422(6934):835–47.
Daar AS, Thorsteinsdóttir H, Martin DK, Smith AC, Nast S, Singer 
PA. (2002) Top ten biotechnologies for improving health in 
developing countries. Nat Genet.;32(2):229–32.
Gold ER (2003) SARS genome patent: symptom or disease? 
Lancet.;361(9374):2002–3.
Juma C & Konde V (2002). The New Bioeconomy: Industrial and 
Environmental Biotechnology in Developing Countries. Geneva, 
Switzerland: United Nations, July 2002.
Lundvall B, Johnson B, Andersen EA, Dalum B (2002) National 
systems of production, innovation and competence building. Research 
Policy;31:213–231
Nasim A (2000) Ethical Issues of the Human Genome Project: An 
Islamic Perspective in Bioethics in Asia. Eubios Ethics Institute Eds: N 
Fujiki and DRJ Macer p. 209–214
Pang T & Weatherall D (2002) Genomics and Global Health. 
BMJ;324:p.1051–52
Singer PA, Daar AS (2001) Harnessing genomics and biotechnology to 
improve global health equity. Science;294(5540):87–9.
Sulston J (2003) Beyond release: the equitable use of genomic 
information.
Lancet.;362(9381):400–2.
Thorsteinsdóttir H, Daar AS, Smith RD, Singer PA (2003) Genomics – 
a global public good?
Lancet.;361(9361):891–2.
Time to Unite Islam and Science. Nature. 2003 Mar 13;422(6928):99.Health Research Policy and Systems 2005, 3:1 http://www.health-policy-systems.com/content/3/1/1
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cussion among the participants following the course, a
brief survey was conducted on the participants' internet
access and their expectations of the network.
Results
Dr Peter A. Singer, Director of the University of Toronto
Joint Centre for Bioethics, described the overall aim of the
course "How to best harness genomics to improve health
in the region", as well as the 4-day program. Dr Ali Jaffer
Suleiman of the Ministry of Health in Oman acted as
chairperson of the meeting.
Professor Riad Bayoumi of Sultan Qaboos University
highlighted new scientific developments that have
resulted from the genomics revolution, such as proteom-
ics; mapping of single nucleotide polymorphisms (SNPs)
to understand human genetic variation and its relation-
ship with disease; gene expression chips to monitor differ-
ential gene expression and identify drug targets; and
bioinformatics as a new field that combines biology,
mathematics, statistics and computer programming to
mine large-scale biological data.
Professor Alexander Capron, Director, Department of Eth-
ics, Trade and Human Rights at WHO, described the 2002
report of the World Health Organization "Genomics and
World Health" [9]. He called attention to the recommen-
dations from the report – these include improving techni-
cal cooperation between WHO and its member states (e.g.
assessing the health impacts of genomics research to sup-
port informed priority setting; capacity building for
genomics research and biotechnology in developing
countries; development of ethical review structures and
bioethics capacity).
Professor Abdallah Daar described a recent study, con-
ducted by the University of Toronto Joint Centre for
Bioethics' Canadian Program on Genomics and Global
Health, to identify the ten most promising biotechnolo-
gies for improving health in developing countries in the
next five to ten years. These technologies offer guidance to
those who can influence the direction of R&D in develop-
ing countries and challenge common assumptions about
the relevance of biotechnology for these countries, as
shown by the mapping of the Top 10 Biotechnologies
onto the UN Millennium Development Goals [10]. How-
ever, to foster biotechnology in developing countries it is
essential to build capacity (among researchers, politicians,
legislators, entrepreneurs, etc).
Professor Al Bar of King Fahad University, Saudi Arabia,
illustrated Islamic perspectives on genetic testing, cloning,
recombinant DNA technology and other genomics-
related technologies. He showed that while Islam and sci-
ence have always been aligned through history, today's
religious leaders in the region must take the initiative to
develop and formulate recommendations for genomics.
Dr. Peter Singer described the concept of innovation sys-
tems and presented some observations of other countries'
innovation systems and their successes. One definition of
a national system of innovation (NSI) is the "network of
institutions in the public and private sector whose activi-
ties initiate, import, modify and diffuse new technolo-
gies" [11-13]. The application of NSI to developing
countries is a fairly recent concept. The Canadian Program
on Genomics and Global Health is currently conducting
studies of the NSI of 7 developing countries: Brazil, China,
Cuba, Egypt, India, South Africa and South Korea [14].
Despite the identification of factors that foster innovation
systems, there is no one model that guarantees success –
each country follows its own unique path.
Mr. Khalil Ahmed, Managing Director of Shantha Biotech-
nics, described the successes of this biotechnology com-
pany based in Hyderabad, India. Shantha was established
in 1993, in part with seed money from the Government of
Oman. Today, it is the first Indian company to receive
WHO certification for a recombinant hepatitis-B vaccine
Shanvac-B™, paving the way for UNICEF to buy 8.5 mil-
lion doses for distribution globally. Hepatitis B vaccine is
currently priced internationally as high as $8–10 per dose,
while Shantha is selling it at $2 per dose [15,16].
Professor Richard Gold of McGill University's Centre for
Intellectual Property Policy described the basics of
intellectual property rights, patents and copyright issues,
as well as policy options for developing countries in the
international context. He outlined the characteristics of
international agreements, which offer considerable
flexibility to countries on how to apply patent laws to
genomics and biotechnology. Developing countries have
a number of options, such as compulsory licensing and
research exemptions, to deal with property rights.
Dr Jayasuriya, Director of UNAIDS in Pakistan described
ways in which legal systems can facilitate best use of bio-
technology. It is essential that legal reform keep up with
the rapidly evolving science of genomics. Health law can
facilitate best use of biotechnology – by providing for fast-
track approval of biotechnology products; reducing
import duties on health interventions; and allowing mul-
tiple channels of procurement and distribution to
improve access and optimize prices.
Dr Anwar Nasim, Chairman of Pakistan's National Coun-
cil of Biotechnology, described the role of regulations
both to promote useful biotechnologies and limit their
risks for human health and the environment. A national-
level regulatory body could provide guidelines for the useHealth Research Policy and Systems 2005, 3:1 http://www.health-policy-systems.com/content/3/1/1
Page 6 of 11
(page number not for citation purposes)
and release of biotechnology products, conduct biosafety
reviews and risk assessments and formulate feedback
mechanisms to improve the system through experience.
The National Commission of Biotechnology of Pakistan,
established in November 2001, focuses on biotechnology
regulatory issues in health, agriculture, environment and
industry. Similar commissions could be set up in other
countries of the region and their interaction could further
regional cooperation in biotechnology.
Mr. Ehsan Masood of Scidev.net pointed out that active
public engagement based upon knowledge can stimulate
action to improve public health. Public engagement is far
greater in today's world than it has ever been in the past.
This is because of several factors including; a) the growing
implications of research on public health, b) the increased
awareness in civil societies to invest in health care and
research, and to influence policy change and action, c)
development and access of information technologies.
On the last day of the course the five participant groups,
who had been assigned the task to on the deliberate the
key question "How best to harness genomics and bio-
technology to improve the health of the people in the
Eastern Mediterranean Region?", were invited to present
their findings. The main points of these group presenta-
tions are summarized in the recommendations that
emerged from the course.
Discussion
The session discussions and group presentations under-
scored the urgent need for action to create the enabling
environments (at regional, national and individual levels)
for research and development in genomics and
biotechnology.
The issue of awareness of biotechnology among political
leaders to garner support at the highest level was raised
early on in the course, and was reinforced throughout the
course discussions. The participants felt strongly that
political commitment is crucial to the advancement of
biotechnology in the region. Political leadership is a criti-
cal factor in raising the profile of science in developing
countries. A prominent example in the Eastern-Mediterra-
nean Region is that of the Sultan Bin Mohammed Al-Qas-
simi, Shaikh of the Arab emirate of Sharjah. He has made
a dedicated effort to change the face of science in the Gulf
[17]. For example, in an attempt to attract Arab scientists
working abroad to return to work in the Gulf, and more
specifically to Sharjah, he has built two universities, six
museums and established a science foundation in just a
decade. He is also actively engaged in creating an environ-
ment of regional cooperation.
The course attendees recommended that WHO-EMRO
should take the responsibility to engage political leaders
in the region's national governments. The participants
shared experiences of the importance of government sup-
port for biotechnology – in Egypt there appears to be rel-
atively strong support for biotechnology by the
government, with biotechnology activity in academic and
other research institutions as well as in the private sector.
In Iran, considerable advances have been made in private
and academic research centres, leading to a number of
biotechnology products that are soon to reach the market,
as well as well-respected scientific journals such as the Ira-
nian Journal of Biotechnology [18]. Other countries such
as Pakistan, Tunisia, Lebanon, and Morocco are making
steady gains in biotechnology, some in conjunction with
their powerful public health sectors and others as a result
of their strong scientific bases.
It will also be crucial to involve, inform and engage reli-
gious leaders in the region in order to promote genomics
and biotechnology for improving public health. In doing
so, it is worthwhile to note that Islam and science have
always been aligned through history and it is well-estab-
lished that Islam has historically contributed tremendous
achievements to the advancement of science. [19] A recent
article argues that the Muslim world has neglected to pay
attention to contemporary ethical issues in science and
technology [20]. The author calls for the establishment of
an independent Islamic bioethics panel to advise Islamic
governments and communities. Other measures, such as
training Muslim bioethicists, incorporating biomedical
issues into school curricula and educating the community
about such issues are also recommended.
The active participation and involvement of organizations
like COMSTECH was recommended to give support and
guidance to WHO-EMRO's efforts. COMSTECH was
established by the Islamic Summit in 1981 and includes
among its objectives the building of indigenous capabili-
ties in the fields of science and technology, promotion
and continuing cooperation and coordination in scien-
tific and technological areas of is member states and crea-
tion of effective institutional structure for planning
research, development and monitoring of scientific and
technological activities. COMSTECH has already
launched networks across the region for exchange of
information, and has valuable experience in the promo-
tion of cooperation and coordination amongst the mem-
ber states in science and technology activities in high
technology areas [21].
A major discussion point at the workshop was the effec-
tive assessment of existing capacity in the region. Several
participants shared disappointment over the relative lack
of participation of the region in global science and tech-Health Research Policy and Systems 2005, 3:1 http://www.health-policy-systems.com/content/3/1/1
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nology advances, citing, for instance, poor representation
of the region at international scientific conferences. Many
felt the need to evaluate and assess the level of scientific
activity and capacity in individual countries in the region,
in order to identify, among other things, strengths and
weaknesses, entry points for countries, opportunities for
regional collaboration, and areas for improvement. The
workshop attendees felt it important to carry out this type
of survey of each country's innovation system as a prereq-
uisite to revising and revamping national and regional
genomics policy. The factors identified by the participants
as important for assessment in this survey – scientific
capacity within public and private sector, private enter-
prise, religious and political leadership and intellectual
property rights – can be considered to be part of the
National System of Innovation (NSI). This proposed sur-
vey of NSI in the region can help to identify factors for suc-
cessful growth of biotechnology sectors. Similarly, the
recently completed study by the Canadian Program on
Genomics and Global Health of the health biotechnology
innovation systems of Brazil, China, Cuba, Egypt, India,
South Africa and South Korea may also help to identify
some of these factors [22]. Workshop participants from
Egypt, Iran, Lebanon, Pakistan, and Tunisia contributed
to the discussion of NSI with descriptions of components
of their countries' biotechnology innovation systems. In
Egypt, there is increased recognition of the importance of
intellectual property rights in fostering innovation. The
Minister of Health has taken a keen interest in improving
linkages between sectors to enhance inter-sectoral com-
munication. The president himself was instrumental in
the establishment of the Mubarak City for Scientific
Research and Technology (MCSRT), which is currently
engaging in collaborative projects with the United States
and with China. Private sector development is of high pri-
ority, as indicated by government support of companies
such as Vacsera, which is now making recombinant insu-
lin in Egypt [23]. One successful story from Egypt is the
development by scientists at the Agricultural Genetic Engi-
neering Research Institute in Giza of a powerful bio-pesti-
cide based on a new strain of Bacillus thuringiensis [24]. In
Iran, the trade embargo has led to a shortage of funds, but
has in some ways helped to strengthen the innovation sys-
tem through the need for self-reliance. Iran and Cuba have
reached an agreement for cooperation and transfer of
technology to produce hepatitis-B vaccine, interferon-α,
streptokinase, and erythropoietin. Iran has developed sev-
eral products based on recombinant DNA technology,
and the country is also actively building research collabo-
ration networks. Pakistan has had some successes in agri-
cultural biotechnology and made some advances in
bioethics. Although there are powerful institutes in place,
the country needs to continue to strengthen facilities,
resources and human capital. There is a need to bring
products to the public. Lebanon has a well-developed
healthcare industry, and has developed expertise in
genetic testing, bioethics as well as intellectual property
rights. Tunisia has strong research infrastructure and has
made advances in genetic counseling, cytogenetics, and
diagnosis of genetic diseases, along with regulation and
legislation. However the pharmaceutical industry is not
able to optimize the potential of public sector research,
for which regional cooperation would be valuable. The
participants identified strengthening the linkages between
academia and the private sector as key to strengthening
capacity in genomics. One example of a concerted effort
to improve academic-private sector links is Jeddah BioC-
ity, a research facility with close ties to the King Faisal Spe-
cialist Hospital and Research Center. Founded by Sultan
Bahabri, head of King Faisal Specialist Hospital and
Research Center in Jeddah and other Saudi scientists, this
private venture plans the construction of state of the art
biotechnology laboratories and companies and is
intended to make Saudi Arabia a world leader in
biotechnology.
As highlighted by the 2004 report of the UN Commission
on Private Sector and Development report [25], the proc-
ess of commercialization for development involves the
dissemination and facilitation of knowledge flows
between public and private sectors of both developed and
developing markets. The report recommends action in
both the public and private spheres, and emphasizes the
linkages between these spheres, recognizing the impor-
tance of cooperation and partnerships to achieve goals.
With stronger public-private linkages, the private sector in
developing countries will be able to help provide new
genomics-based technologies at affordable prices. Given
that over the last few decades, market forces have driven
the R&D agenda of pharmaceutical companies based in
the North to de-emphasize the health concerns of devel-
oping countries, it is becoming increasingly important to
develop indigenous capacity in private enterprise. The
successes of biotechnology firms in developing countries
such as India and Egypt were seen as a source of inspira-
tion by the course attendees.
The attendees observed that the key to effective participa-
tion in the genomics revolution is building scientific
capacity, and expressed serious concern over the region's
limited capacity to absorb and utilize genomics and bio-
technology. Critical to capacity-building is access not just
to technology but, more importantly, to scientific knowl-
edge. One point-of-entry that was greeted with enthusi-
asm by the participants was bioinformatics, which is
typically less-resource intensive compared with other
genomics-related sciences, such as sequencing and pro-
teomics. According to the report on the "Top 10 technol-
ogies to improve health in developing countries"
countries of EMR can take advantage of genomic data andHealth Research Policy and Systems 2005, 3:1 http://www.health-policy-systems.com/content/3/1/1
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apply the power of bioinformatics to local health prob-
lems without having to invest heavily in the technologies
used to produce them, A dedicated Genomics and Health
Research Fund for the region may help to break down
financial barriers to encourage scientific research and
development in the region.
The participants expressed enthusiasm for setting up
National Biotechnology Commissions to address genom-
ics policies at the national level and to contribute to the
development of the above-mentioned national biotech-
nology strategy. A National Commission on Biotechnol-
ogy (NCB) has been set up in Pakistan. The overall goal
would be to help devise regulations to facilitate innova-
tion in biotechnology. The NCB could help coordinate
national biotechnology activities and policy, with activi-
ties including evaluation of biotechnology capacity (see
above) to priority setting and public engagement. Accord-
ingly, the NCB should have broad cross-sectoral represen-
tation in order to minimize the negative effects of inter-
institutional rivalry. One of the main goals of the NCB (or
equivalent national agency), following the above-men-
tioned national biotechnology survey, will be to help
develop and adopt a national biotechnology strategy, per-
haps as part of a long-term science and technology policy.
Other important objectives are discussed below.
At the outset of the conference, participants voiced their
concern about the low level of awareness (which goes
beyond just public  awareness) of biotechnology and
genomics in the region, and that this lack of awareness
may be the biggest barrier to advances in genomics. Public
awareness and engagement can help change the pace of
research, leading to increased opportunities for greater
societal involvement for improved health care. Media can
be used as a catalyst to raise community awareness for
social beneficence, equity and justice in health care.
Recently, in May 2004, science journalists from across the
region met in Cairo to discuss the hurdles they face in sci-
ence reporting. The hurdles identified at this meeting
included bureaucracy and poor access to scientific
research taking place in the region [26]. The meeting con-
cluded with the creation of a provisional network of Arab
science journalists that will aim to provide its members
with training, skills and contacts, as well as promote the
coverage of scientific issues from a development perspec-
tive. Similarly, public health specialists and scientists
should also be encouraged to engage actively disseminate
evidence based and correct information in disease preven-
tion and control through media.
While it was agreed that science should be permitted to
march forward, the participants emphasized that ethics,
regulations and laws must keep up with the science [27].
For example, an important focus area of the NCB is that of
intellectual property rights. The participants agreed that
developing countries must build capacity and knowledge
to choose the best policy options to benefit from the inter-
national patent regime. Compulsory licensing under spe-
cific circumstances may be a good option for developing
countries and national laws should permit compulsory
licensing [28]. The forces of globalization must balance
forces of protectionism, especially by the developed
world, and both national and regional regimes should
respect international patent law to take advantage of glo-
balization. If developing countries are involved in inter-
national research collaborations, they should ensure that
they obtain patents. In view of this, it is essential for devel-
oping countries to build capacity and training in patent
law and learn how to formulate effective patents, and the
NCB could play a key role in this effort.
Regional cooperation in science was given a boost this
year, with the establishment of a network of science acad-
emies of the Organisation of Islamic Conference [29] at a
meeting organized by the Third World Academy of Sci-
ences. This formal network aims to provide the partner
states with mutual support and supports discussion of the
scientific aspects of common problems. It could help to
build a unified approach to capacity building in science
and technology within member states.
Health advances in developing countries have lagged
behind those in the developed world. The rapid advance
in genomics research in developed countries compared
with the relatively slow progress of genomics R&D in
developing countries threatens to create a North-South
genomics divide in the coming years, which may enhance
existing health inequities. With the appropriate emphasis
on its health needs, incentives for public-private R&D
partnerships, and a sound set of regulatory policies, the
Eastern Mediterranean Region may well reap the benefits
of genomics and biotechnology. The overall goal of the
Genome Policy Executive Course, a WHO-University of
Toronto initiative, was to help provide the impetus for
cross-sectoral dialogue on genomics and health policy in
the region. The internet-based opinion leaders' network is
expected to foster dialogue to help achieve the objectives
outlined by the participants of the course.
The participants and the organizers of the course felt
strongly that the recommendations formulated at the
course must be shepherded by individuals. People felt
that progress could be achieved if individuals make a sig-
nificant and concerted effort to ensure that these recom-
mendations are fulfilled.
One way to spur action and maintain the momentum
generated by this course is by coordinating the partici-
pants into a network within which they can continue toHealth Research Policy and Systems 2005, 3:1 http://www.health-policy-systems.com/content/3/1/1
Page 9 of 11
(page number not for citation purposes)
interact and share information and experiences. This
internet-based network will be moderated in order to
streamline discussions. A number of short-term projects
are envisioned that could be coordinated by various
expert members of the network. The results of the survey
(table 4) administered to the participants during the
course suggested that 80% of them had reliable access to
internet and would be willing to spend 1–2 hours a week
taking part in the discussion. The main objectives of the
network, as identified by the participants in the survey,
would be dissemination of information, exchange of
ideas, maintaining inter-connectivity, consensus building
Table 4: Opinion leaders' network survey results in brief
Goals of network • Dissemination of information
• Exchange of ideas
• Maintaining inter-connectivity
• Consensus building through wide participation
• Influencing policy and media
Access • 41 (79%) no access issues – reliable connectivity from work
• 3 needed some assistance with email access (internet connection at work; compensation for access; help to post 
responses)
Obstacles to participation • 47 (92%) identified lack of time due to professional responsibilities
• 98% of those with connectivity willing to dedicate 1 hour a week to the network
• 3 people identified lack of connectivity as a barrier
Table 5: Recommendations
Recommendations for the Eastern Mediterranean Regional Office
The workshop recommends that the Regional Director EMRO may be requested to address the governments at the highest level for actively 
considering the proposals of this workshop and for giving priority attention to genomics for health and health biotechnology. The political 
leadership may be provided effective advocacy material, with special reference to its link with poverty alleviation, public health objectives, and need 
for transfer (and internalization) of technology.
EMRO and Organization of the Islamic Conference Standing Committee for Science and Technology (COMSTECH), and possibly other groups 
should provide coordination and networking among national biotechnology bodies (see below) and coordinators to exchange information, 
expertise, training, and Regional cooperation in production and utilization of health biotechnology.
EMRO, in collaboration with member states and their national biotechnology bodies, should coordinate a national survey/inventory/situation 
analysis/needs assessment of health biotechnology innovation systems, including scientific and management capacity, government policies, legislation 
and regulations, intellectual property policies, private sector activity, and strengths/weaknesses, opportunities and threats.
EMRO, in collaboration with COMSTECH and member states, should develop a proposal/feasibility study for a Regional Genomics and Health 
Research Fund emphasizing both peer-reviewed research and capacity strengthening.
Recommendations for Member States
Each member state should create an effective National Commission on Genomics, Biotechnology and Health, if this function has not otherwise 
been established, including a coordinator who will serve as the focal point for this activity. The membership should be multisectoral and include 
youth, women, and civil society. The focus should include ethical issues.
Based on evidence from the national survey described above, governments of member states should develop and adopt, at the highest level, a 
national biotechnology strategy.
The National Commission on Biotechnology should develop programs of public awareness and engagement. Important "publics" here include media 
and religious leaders as well as the public at large. The discussion should include ethical issues.
The National Commission on Biotechnology should encourage academic institutions including schools and universities, to include health 
biotechnology topics within their curricula and create specialized programs and degrees where appropriate. There should be particular emphasis on 
ICT and bioinformatics.
The National Commission on Biotechnology, in collaboration with the relevant ministries, should develop a plan to integrate genetic and genomics 
products (including diagnostics, vaccines, therapies, and other genomic priorities), within the health system and public health programs. The 
emphasis should be on accessibility and equity to improve the health of the poor.
Recommendations for Individuals
There is a need for strong personal commitment to strengthen the initiative on genomics and biotechnology to improve health and well-being of 
people in the EMRO Region. Workshop participants, as well as other concerned individuals, should are therefore encouraged to actively engage in 
the implementation of these recommendations.Health Research Policy and Systems 2005, 3:1 http://www.health-policy-systems.com/content/3/1/1
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through wide participation, and influencing policy and
media. The network is now established and is being used
by the participants to exchange information.
Conclusions
The meeting concluded with a set of recommendations for
the EMRO and Member States (table 5) [30]. The recom-
mendations were developed through consensus among
the participants. The process of consensus development
involved the following steps: (i) the recommendations
were drafted based on the group presentations, (ii) any
recommendations which the participants did not support
were deleted (iii) recommendations that were missing but
deemed to be important were added (iv) the final list was
scrutinized to sharpen language and consolidate points
where possible.
The participants felt the need for EMRO to:
a) Request regional governments and policy makers at
highest level to give priority to genomics for health and
health biotechnology
b) Develop linkages with Organization of Islamic Confer-
ence Standing Committee for Science and Technology
(COMSTECH) and other international partners to build
Regional networking and cooperation for developing and
utilizing health biotechnology.
c) In collaboration with Member States undertake a
national survey/situation analysis/needs assessment of
health biotechnology innovation systems including
resource capacities, government policies (legislation,
regulations intellectual property policies and private sec-
tor activity.
d) In collaboration with COMSTECH initiate a research
grant for applied (health) genomics and biotechnology
The participants agreed that each member state would
benefit from creating effective National Commissions on
Biotechnology (NCB) to develop national biotechnology
strategies. NCB should; a) develop national priorities,
programmes and guidelines aimed at raising public edu-
cation and awareness and b) collaborate with civil sectors
to develop plans to integrate genetic and genomic prod-
ucts (including diagnostics, vaccines, therapies and other
genomic priorities within the health systems and public
health programmes and c) build capacities for utilization
and access of health biotechnology to the needy and e)
ensure ethical safeguards against unwanted harm and
exploitation and improve equity to improve health of the
poor. The participants also felt that there was a need for
strong personal commitment at individual level by
experts and key actors to engage actively in the implemen-
tation of the recommendations to strengthen the initiative
on genomics and biotechnology to improve the health
and well-being of people in EMR. One concrete outcome
of the workshop that may contribute to strengthening
capacity in the region is the joint agreement between
WHO/EMRO and the University of Toronto Joint Centre
for Bioethics to provide scholarships to the Master of
Health Sciences Program at the JCB. Furthermore, there
seems to be growing need to establish a Regional Health
Biotechnology Network for EMR, and WHO-EMRO is
now planning to hold a Regional meeting to discuss this
in Iran in July 2004.
WHO-EMRO has initiated follow-up of these recommen-
dations. Ministers of Health from the region, at the 50th
Regional Committee Meeting held in October 2003,
urged Member States to establish national bodies for
genomics and biotechnology to formulate strategic vision
for creating public awareness and for developing biotech-
nology for equitable health care in the region.
Recently, a paper on harnessing genomics and biotech-
nology for public health was presented at the EM 28th
Regional Consultative Committee Meeting (RCC) held in
Cairo in April of this year. The recommendations in the
paper were derived from those developed at the
workshop. The paper will be presented at this year's
Regional Committee Meeting to be held in October 2004.
The methods and recommendations outlined in this
paper demonstrate progress in bringing genomics and
biotechnology to the forefront of science policy in devel-
oping countries. Our procedure has now led to the forma-
tion of three regional networks – the two previous ones
being the African Genome Policy Forum, which encom-
passes participants from 10 African nations, the Indian
Genome Policy Forum. We have also now held a course
for Latin America and the Caribbean in association with
PAHO and the UN University in Venezuela May 23–26
2004, and a similar network is being created of partici-
pants of that course. The next one will be held in the
Southeast Asian region, most likely based in Hong Kong.
These regional genome policy networks will provide mod-
els to establish a Global Genome Policy Forum.
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